405 related articles for article (PubMed ID: 25586536)
1. Immunological differences between classical phenothypes of multiple sclerosis.
Iwanowski P; Losy J
J Neurol Sci; 2015 Feb; 349(1-2):10-4. PubMed ID: 25586536
[TBL] [Abstract][Full Text] [Related]
2. Primary progressive multiple sclerosis: part of the MS disease spectrum or separate disease entity?
Antel J; Antel S; Caramanos Z; Arnold DL; Kuhlmann T
Acta Neuropathol; 2012 May; 123(5):627-38. PubMed ID: 22327362
[TBL] [Abstract][Full Text] [Related]
3. Pathogenic Mechanisms Associated With Different Clinical Courses of Multiple Sclerosis.
Lassmann H
Front Immunol; 2018; 9():3116. PubMed ID: 30687321
[TBL] [Abstract][Full Text] [Related]
4. Treatment effects of immunomodulatory therapies at different stages of multiple sclerosis in short-term trials.
Bates D
Neurology; 2011 Jan; 76(1 Suppl 1):S14-25. PubMed ID: 21205678
[TBL] [Abstract][Full Text] [Related]
5. Multiple sclerosis by phenotype in Germany.
Engelhard J; Oleske DM; Schmitting S; Wells KE; Talapala S; Barbato LM
Mult Scler Relat Disord; 2022 Jan; 57():103326. PubMed ID: 35158442
[TBL] [Abstract][Full Text] [Related]
6. Voxel-based assessment of differences in damage and distribution of white matter lesions between patients with primary progressive and relapsing-remitting multiple sclerosis.
Di Perri C; Battaglini M; Stromillo ML; Bartolozzi ML; Guidi L; Federico A; De Stefano N
Arch Neurol; 2008 Feb; 65(2):236-43. PubMed ID: 18268194
[TBL] [Abstract][Full Text] [Related]
7. Increased socioeconomic burden in patients with primary progressive multiple sclerosis: A Danish nationwide population-based study.
Blinkenberg M; Kjellberg J; Ibsen R; Magyari M
Mult Scler Relat Disord; 2020 Nov; 46():102567. PubMed ID: 33296969
[TBL] [Abstract][Full Text] [Related]
8. CXCL10 and CXCL13 chemokines in patients with relapsing remitting and primary progressive multiple sclerosis.
Iwanowski P; Losy J; Kramer L; Wójcicka M; Kaufman E
J Neurol Sci; 2017 Sep; 380():22-26. PubMed ID: 28870573
[TBL] [Abstract][Full Text] [Related]
9. Serious infections in patients with relapsing and progressive forms of multiple sclerosis: A German claims data study.
Knapp R; Hardtstock F; Krieger J; Wilke T; Maywald U; Chognot C; Muros-Le Rouzic E; Craveiro L
Mult Scler Relat Disord; 2022 Dec; 68():104245. PubMed ID: 36306609
[TBL] [Abstract][Full Text] [Related]
10. Genetic differences between primary progressive and relapsing-remitting multiple sclerosis: The impact of immune-related genes variability.
Kiselev I; Bashinskaya V; Baulina N; Kozin M; Popova E; Boyko A; Favorova O; Kulakova O
Mult Scler Relat Disord; 2019 Apr; 29():130-136. PubMed ID: 30711878
[TBL] [Abstract][Full Text] [Related]
11. Patients with progressive multiple sclerosis have elevated antibodies to neurofilament subunit.
Silber E; Semra YK; Gregson NA; Sharief MK
Neurology; 2002 May; 58(9):1372-81. PubMed ID: 12011283
[TBL] [Abstract][Full Text] [Related]
12. In vivo evidence of oxidative stress in brains of patients with progressive multiple sclerosis.
Choi IY; Lee P; Adany P; Hughes AJ; Belliston S; Denney DR; Lynch SG
Mult Scler; 2018 Jul; 24(8):1029-1038. PubMed ID: 28569645
[TBL] [Abstract][Full Text] [Related]
13. Onset of progressive phase is an age-dependent clinical milestone in multiple sclerosis.
Tutuncu M; Tang J; Zeid NA; Kale N; Crusan DJ; Atkinson EJ; Siva A; Pittock SJ; Pirko I; Keegan BM; Lucchinetti CF; Noseworthy JH; Rodriguez M; Weinshenker BG; Kantarci OH
Mult Scler; 2013 Feb; 19(2):188-98. PubMed ID: 22736750
[TBL] [Abstract][Full Text] [Related]
14. A patient with established primary progressive multiple sclerosis transitions to 'secondary' relapsing-remitting disease course following a fulminant demyelinating episode.
Tutuncu M; Demirci NO; Özer F; Saip S; Kantarci OH; Siva A
Mult Scler; 2011 Oct; 17(10):1262-4. PubMed ID: 21135019
[TBL] [Abstract][Full Text] [Related]
15. Natural history of multiple sclerosis: a unifying concept.
Confavreux C; Vukusic S
Brain; 2006 Mar; 129(Pt 3):606-16. PubMed ID: 16415308
[TBL] [Abstract][Full Text] [Related]
16. Progressive multiple sclerosis cerebrospinal fluid induces inflammatory demyelination, axonal loss, and astrogliosis in mice.
Cristofanilli M; Rosenthal H; Cymring B; Gratch D; Pagano B; Xie B; Sadiq SA
Exp Neurol; 2014 Nov; 261():620-32. PubMed ID: 25111532
[TBL] [Abstract][Full Text] [Related]
17. CSF inflammation and axonal damage are increased and correlate in progressive multiple sclerosis.
Romme Christensen J; Börnsen L; Khademi M; Olsson T; Jensen PE; Sørensen PS; Sellebjerg F
Mult Scler; 2013 Jun; 19(7):877-84. PubMed ID: 23178691
[TBL] [Abstract][Full Text] [Related]
18. Gene expression analysis of relapsing-remitting, primary progressive and secondary progressive multiple sclerosis.
Ratzer R; Søndergaard HB; Christensen JR; Börnsen L; Borup R; Sørensen PS; Sellebjerg F
Mult Scler; 2013 Dec; 19(14):1841-8. PubMed ID: 24085340
[TBL] [Abstract][Full Text] [Related]
19. The relation between inflammation and neurodegeneration in multiple sclerosis brains.
Frischer JM; Bramow S; Dal-Bianco A; Lucchinetti CF; Rauschka H; Schmidbauer M; Laursen H; Sorensen PS; Lassmann H
Brain; 2009 May; 132(Pt 5):1175-89. PubMed ID: 19339255
[TBL] [Abstract][Full Text] [Related]
20. Altered maturation of circulating dendritic cells in primary progressive MS patients.
López C; Comabella M; Al-zayat H; Tintoré M; Montalban X
J Neuroimmunol; 2006 Jun; 175(1-2):183-91. PubMed ID: 16698091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
